Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Autologous CAR-T | 2 |
Toxin | 2 |
Herbal medicine | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism SNAP25 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SNAP25 modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Start Date19 Mar 2024 |
Sponsor / Collaborator |
Start Date14 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Recombinant botulinum toxin type A (MingMed Biotechnology) ( SNAP25 ) | Glabellar frown lines More | Phase 3 |
PRJ1-3024 ( HPK1 ) | Advanced Malignant Solid Neoplasm More | Phase 2 Clinical |
QA-102 | dry age-related macular degeneration More | Phase 2 |
YY003 ( SNAP25 ) | Glabellar frown lines More | Phase 2 |
QA108 | Age Related Macular Degeneration More | Phase 2 |